Iovance Biotherapeutics is trading at $9.76, up +4.27%, outperforming the broader biotech sector, which is down 2.11% during the regular session.
- No new company-specific announcement dated September 15 or September 16, 2026, was identified.
- A September 10 conference report highlighted AMTAGVI momentum and an improving outlook but did not explicitly connect those comments to the stock’s move.
- The catalyst remains unconfirmed; early-session volatility and broader risk-on market sentiment may be contributing.